Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations

Journal of Clinical Epidemiology

Volumn 62, Issue 12, 2009, Pages 1268-1278

  Odierna, Donna H ^a   Bero, Lisa A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Evidence based health policy; Evidence based medicine; Health disparities; Health equity; Medicaid; Systematic review

Indexed keywords

ANALGESIC AGENT; ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; HORMONE; PSYCHOTROPIC AGENT;

AFRICAN AMERICAN; ARTICLE; DRUG EFFECT; DRUG FORMULARY; DRUG SAFETY; ETHNIC DIFFERENCE; ETHNICITY; EUROPEAN AMERICAN; HEALTH CARE POLICY; HISPANIC; HUMAN; MEDICAID; MINORITY GROUP; POPULATION; POVERTY; PRIORITY JOURNAL; QUALITY CONTROL; RACE DIFFERENCE; SEX DIFFERENCE; SOCIAL STATUS; SYSTEMATIC REVIEW; UNITED STATES;

ETHNIC GROUPS; EVIDENCE-BASED MEDICINE; FEMALE; FORMULARIES AS TOPIC; HEALTH POLICY; HEALTH STATUS DISPARITIES; HUMANS; MALE; MEDICAID; MINORITY GROUPS; PATIENT SELECTION; POVERTY; REVIEW LITERATURE AS TOPIC; SEX FACTORS; UNITED STATES;

EID: 70449099267     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2009.01.009     Document Type: Article

References (95)

1. World Health Organization. Equitable access to essential medicines: a framework for collective action. In: W.H.O. (Ed). WHO policy perspectives on medicines (2004), World Health Organization, Geneva, Switzerland
2. World Health Organization. How to develop and implement a national drug policy. In: W.H.O. (Ed). WHO policy perspectives on medicine. 2nd edition (2001), W.H.O., Geneva, Switzerland
3. McElwee N.E., Ho S.Y., McGuigan K.A., and Horn M.L. Evidence-based coverage decisions? Primum non nocere. Health Aff 25 4 (2006) 279-282
4. Whitehead M. The concepts and principles of equity and health. Health Promot Int 6 3 (1991) 217-228
5. Tugwell P., de Savigny D., Hawker G., and Robinson V. Applying clinical epidemiological methods to health equity: the equity effectiveness loop. BMJ 332 7537 (2006) 358-361
6. Kravitz R.L., Duan N., and Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 82 4 (2004) 661-687
7. Centers for Medicaid and Medicare Services Overview. U.S. Department of Health and Human Services. Available at: http://www.cms.hhs.gov/pf/printpage.asp?ref=http://www.cms.hhs.gov/Medic aidGenInfo/01_Overview.asp. Accessed November 14, 2008.
8. Oregon Health and Science University. Drug effectiveness review project (DERP) (2008). http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/index.cfm Portland, OR. Available at: http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/index.cfm. Accessed June 26, 2008
9. Elam L., Murawski M.M., Childs S., and Vanable Jr. J.W. Patient safety forum: do state Medicaid preferred drug lists affect patient safety?. Psychiatr Serv 56 8 (2005) 1012-1016
10. Crowley J., and Ashner D. State Medicaid outpatient prescription drug policies: findings from a national survey, 2005 update. Kaiser commission on Medicaid and the uninsured (2005), Kaiser Family Foundation, Washington, DC
11. Canadian Agency for Drugs and Technologies in Health. Common drug review (2008), Canadian Agency for Drugs and Technologies in Health, Ottawa, ON
12. Higgins J., and Green S. Cochrane handbook for systematic reviews of interventions version 5.0.0. Updated February 2008. In: The Cochrane Collaboration (Ed) (2008). Available at www.cochrane-handbook.org Accessed July 30, 2008
13. Neumann P.J. Emerging lessons from the drug effectiveness review project. Health Aff 25 4 (2006) W262-W271
14. Heaton A.H. The DERP: is it an effective methodology?. Health Aff 25 4 (2006) W276-W278
15. Bero L.A., and Jadad A.R. How consumers and policymakers can use systematic reviews for decision making. Ann Intern Med 127 1 (1997) 37-42
16. Sweet M., and Moynihan R. Improving population health: the uses of systematic reviews (2007), Milbank Memorial Fund and Centers for Disease Control and Prevention, New York and Atlanta
17. Findlay S.D. Bringing the DERP to consumers: 'consumer reports best buy drugs'. Health Aff 25 4 (2006) W283-W286
18. Moynihan R. In: Millbank Memorial Fund (Ed). Evaluating health services: a reporter covers the science of research synthesis (2004) New York
19. Fox D.M. Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions. Health Aff 24 1 (2005) 114-122
20. Jewell C., and Bero L. Developing good taste in evidence: facilitators and hindrances to evidence-informed health policy making in state government. Milbank Q 86 2 (2008) 177-208
21. U.S. Department of Health and Human Services. State strategies to contain Medicaid drug costs. In: Office of Inspector General (Ed) (2003). http://www.oig.hhs.gov/oei/reports/oei-05-02-00680.pdf Accessed October 1, 2008
22. Lexchin J., Bero L.A., Djulbegovic B., and Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326 7400 (2003) 1167-1170
23. Yank V., Rennie D., and Bero L.A. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ 335 7631 (2007) 1202-1205
24. Jorgensen A.W., Hilden J., and Gotzsche P.C. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 333 7572 (2006) 782
25. Gibson M. When good information truly matters: public sector decision makers acquiring and using research to inform their decisions. J Law Policy XIV 2 (2006) 551-568
26. Soumerai S.B. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 23 (2004) 135-146
27. Weiss N.S., Koepsell T.D., and Psaty B.M. Generalizability of the results of randomized trials. Arch Intern Med 168 2 (2008) 133-135
28. Sackett D.L., Rosenberg W.M.C., Gray J.A.M., Haynes R.B., and Richardson W.S. Evidence based medicine: what it is and what it isn't. BMJ 312 7023 (1996) 71-72
29. Centers for Medicaid and Medicare Services. Fiscal year 2004 national MSIS tables, in Medicaid statistical information system state summary FY2004. Available at (2007). http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/Downloads/msistables20 04.pdf Accessed July 30, 2008
30. Hussain-Gambles M., Atkin K., and Leese B. Why ethnic minority groups are under-represented in clinical trials: a review of the literature. Health Soc Care Community 12 5 (2004) 382-388
31. Heiat A., Gross C.P., and Krumholz H. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 162 (2002) 1682-1688
32. Lee P., Alexander K., Bradley G., Pasquali S., and Peterson E. Representation of elderly persons and women in trials of acute coronary syndromes. JAMA 296 6 (2001) 708-713
33. Rochon P., Mashari A., Cohen A., Anjali M., Laxer D., and Streiner DL. The Inclusion of minority groups in clinical trials: problems of under representation and under reporting of data. Account Res 11 3-4 (2004) 215-223
34. Roberts D. Is race-based medicine good for us? African American approaches to race, biomedicine, and equality. J Law Med Ethics 36 3 (2008) 471-477
35. Swanson G.M., and Bailar J.C. Selection and description of cancer clinical trials participants-science or happenstance?. Cancer 95 5 (2002) 950-959
36. Van Spall H.G.C., Toren A., Kiss A., and Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals. JAMA 297 11 (2007) 1233-1240
37. Liggett S.B., Cresci S., Kelly RJ., Syed FM., Matkovich SJ., Hahn HS., et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nature 14 (2008) 510-517
38. Exner D., Dries D., Domanski M., and Cohen J. Lesser response to angiotensis-converting enzyme inhibitor therapy in black compared to white patients with left ventricular dysfunction. NEJM 344 18 (2001) 1351-1357
39. Cotton P. Examples abound of gaps in medical knowledge because of groups excluded from scientific study. JAMA 263 8 (1990) 1051-1055
40. Braun L., Fausto-Sterling A., Fullwiley D., Hammonds E.M., Nelson A., Quivers W., et al. Racial categories in medical practice: how useful are they?. PLoS Med September 1 4 9 (2007) e271 doi:10.1371/journal.pmed.0040271
41. Epstein S. Inclusion: the politics of difference in medical research (2007), University of Chicago Press, Chicago, IL
42. Krieger N., and Fee E. Man-made medicine and women's health: the biopolitics of sex/gender and race/ethnicity. In: Krieger N. (Ed). Embodying inequality: epidemiologic perspectives (2004), Baywood, Amityville, NY 239-256
43. Kawachi I., Daniels N., and Robinson D.E. Health disparities by race and class: why both matter. Health Aff 24 2 (2005) 343-352
44. Ellison G.T.H., et al. Racial categories in medicine: a failure of evidence-based practice?. PLoS Medicine. September 01 4 9 (2007) e287 doi:210.1371/journal.pmed.0040287
45. Caulfield T., and Harry S. Popular representation of race: the news coverage of Bidil. J Law Med Ethics 36 3 (2008) 485-490
46. Obasogie O.K. Beyond best practices: strict scrutiny as a regulatory model for race-specific medicines. J Law Med Ethics 36 3 (2008) 491-497
47. Winker M.A. Measuring race and ethnicity: why and how?. JAMA 292 13 (2004) 1612-1614
48. Zuberi T. Thicker than blood: how racial statistics lie (2001), Regents of University of Minnesota, Minneapolis, MN
49. van den Oord E., and Rowe D.C. A step in another direction: looking for maternal genetic and environmental effects on racial differences in birth weight. Demography 38 4 (2001) 573-576
50. Sankar P., and Kahn J. BiDil: race medicine or race marketing?. Health Aff 10.1377/ October 11 (2005) hlthaff.w5.455-463
51. Fine M.J., Ibrahim S.A., and Thomas S.B. The role of race and genetics in health disparities research. Am J Public Health (2005) 076588
52. Navarro V. Race or class versus race and class: mortality differentials in the United States. Lancet 336 8725 (1990) 1238-1240
53. Kaufman J. Epidemiologic analysis of racial/ethnic disparities: some fundamental issues and a cautionary example. Soc Sci Med 66 (2008) 1659-1669
54. van den Oord E., and Rowe D.C. Racial differences in birth health risk: a quantitative genetic approach. Demography 37 3 (2000) 285-298
55. Williams D.R., and Jackson P.B. Social sources of racial disparities in health. Health Aff 24 2 (2005) 325-334
56. Doyle J.M. What race and ethnicity measure in pharmacologic research. J Clin Pharmacol 46 4 (2006) 401-404
57. Gwatkin D.R. Health inequalities and the health of the poor: what do we know? What can we do?. Bull World Health Organ 78 (2000) 3-17
58. Syme S.L., and Berkman L. Social class, susceptibility, and sickness. Am J Epidemiol 104 (1976) 1-8
59. Marmot M. Social determinants of health inequalities. Lancet 365 9464 (2005) 1099-1104
60. In: Syme S., and Reeder L. (Eds). Social stress and cardiovascular disease Vol. 45 (1967), Milbank Memorial Fund Quarterly, New York
61. Kawachi I., and Subramanian S.V. Neighbourhood influences on health. J Epidemiol Community Health 61 1 (2007) 3-4
62. Krieger N. Discrimination and health. In: Berkman L., and Kawachi I. (Eds). Social epidemiology (2000), Oxford University Press, Oxford 36-75
63. Berkman L., and Glass T. Social integration, social networks, social support, and health. In: Berkman L., and Kawachi I. (Eds). Social epidemiology (2000), Oxford University Press, New York 137-173
64. McEwen B.S. Protective and damaging effects of stress mediators. N Engl J Med 338 3 (1998) 171-179
65. Todd K.H., Deaton C., D'Adamo A., and Goe L. Ethnicity and analgesic practice. Ann Emerg Med 35 (2000) 11-16
66. Subramanian S.V., Chen JT., Rehkopf DH., Waterman PD., and Krieger N. Racial disparities in context: a multilevel analysis of neighborhood variations in poverty and excess mortality among black populations in Massachusetts. Am J Public Health 95 (2005) 260-265
67. Link B.G., and Phelan J. Social conditions as fundamental cause of disease. J Health Soc Behav Extra Issue (1995) 80-94
68. Paul K., Boutain D., Manhart L., and Hitti J. Racial disparity in bacterial vaginosis: the role of socioeconomic status, psychological stress, and neighborhood characteristics, and possible implications for preterm birth. Soc Sci Med 67 (2008) 824-833
69. Wang Y., Krishnsn H.R., Ghezzi A., Yin J.C.P., and Atkinson N.S. Drug-induced epigenetic changes produced drug tolerance. PLoS Biol 5 10 (2007) e265
70. Peedicayil J. The role of epigenetics in mental disorders. Indian J Med Res 126 August (2007) 105-111
71. Francis D.D., Szegda K., Campbell G., Martin WD., and Insel TT. Epigenetic sources of behavioral differences in mice. Nat Neurosci 6 5 (2003) 445-446
72. Oregon Health and Science University. Documents: drug effectiveness review project final products. Drug Effectiveness Review Project (2008), Oregon Health and Science University. http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/final-produ cts.cfm Accessed April 27, 2008
73. Oregon Health and Science University. DERP methods. Drug Effectiveness Review Project (2008), Oregon Health & Science University. http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm Portland, OR Accessed April 29, 2008
74. The Kaiser Family Foundation, State Health Facts, statehealthfacts.org. Data Source: Centers for Medicare and Medicaid Services and U.S. Census Bureau Current Populations Surveys. The Kaiser Family Foundation. Available at (2008). http://www.statehealthfacts.org/ Accessed April 27, 2008
75. The Kaiser Family Foundation, State Health Facts, Methodology, statehealthfacts.org, Sourcing, and Contact Information. 2008. Accessed August 1, 2008.
76. Centers for Medicaid and Medicare Services. Medicaid at a glance 2005: a Medicaid information source (2005), US Department of Health and Human Services, Washington, DC. http://www.cms.hhs.gov/MedicaidGenInfo/Downloads/MedicaidAtAGlance2005.p df Accessed July 30, 2008
77. Centers for Medicaid and Medicare Services. Medicaid data sources-general information (2008), U.S. Department of Health and Human Services. http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/02_MSISData.asp Accessed July 30, 2008
78. U.S. Census Bureau. State & county quickfacts. In: A.f.h.q.c.g.q.s.h. U.S. Census Bureau (Ed). QuickFacts (2007)
79. U.S. Census Bureau. Profile of general demographic characteristics: 2006. American FactFinder (2007). Available at http://factfinder.census.gov/home/saff/main.html%3F_lang=en Accessed April 24, 2008
80. Mann J. Medicine and public health, ethics, and human rights (Hastings Center Report, 1997). In: Beauchamp D.E., and Steinbock B. (Eds). New ethics for the public's health (1999) 83-93
81. Bartlett C., Davey P., Dieppe P., Doyal L., Ebrahim S., and Egger M. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart 89 (2003) 327-328
82. Wendler D., Kington R., Madans J., Wye GV., Christ-Schmidt H., Pratt LA., et al. Are racial and ethnic minorities less willing to participate in health research?. PLoS Med 3 2 (2006) e19
83. Dhruva S.S., and Redberg R.F. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare coverage decisions. Arch Intern Med 168 2 (2008) 136-140
84. Tugwell P., Robinson V., and Kristjansson E. The role of clinical epidemiology in health equity: let's take action!. J Clin Epidemiol 58 8 (2005) 751-752
85. MacLehose R., Reeves B., Harbvey I., Sheldon T., Russell I., and Black A. A systematic review of comparisons of effect sizes derived from randomized and non-randomized studies. Health Technol Assess 4 34 (2000) 1-154
86. Mechanic D. Policy challenges in addressing racial disparities and improving population health. Health Aff 24 2 (2005) 335-338
87. CSDH. Closing the gap in a generation: health equity through action on the social determinants of health (2008), World Health Organization, Geneva, Switzerland
88. Pollock A. Pharmaceutical meaning-making beyond marketing: racialized subjects of generic Thiazide. J Law Med Ethics 36 3 (2008) 530-536
89. Rothwell P.M. Subgroup analysis in randomized controlled trials: importance, indications, and interpretation. Lancet 365 9454 (2005) 176-186
90. Oxman A.D., and Guyatt G.H. A consumer's guide to subgroup analyses. Ann Intern Med 116 1 (1992) 78-84
91. Warnecke R.B., Oh A., Breen N., Gehlert S., Paskett E., and Tucker K.L. Approaching health disparities from a population perspective: the National Institutes of Health Centers for Population Health and health disparities. Am J Public Health 98 9 (2008) 1608-1615
92. Kavaganagh J., Oliver S., and Lorenc T. Reflections on developing and using PROGRESS-Plus. In: Tugwell P., Welch V., and Morris E. (Eds). Equity update (2008), The Cochrane Collaboration, Ottawa, ON
93. Evans T., and Brown H. Road traffic crashes: operationalizing equity in the context of health sector reform. Inj Control Saf Promot 10 1-2 (2002) 11-12
94. Lexchin J. Effects of restrictive formularies in the ambulatory care setting. Am J Manag Care 8 1 (2001) 69-76
95. Johnson T.J., and Stahl-Moncada S. Medicaid prescription formulary restrictions and arthritis treatment costs. Am J Public Health 98 7 (2008) 1300-1305